1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd.

KKRX:214450
239,500.00
KRW
-15,500.00
(-6.08%)
15,648.29EPS
17.60P/E
3.11TMarket Cap
Nov 18Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,152.8
4,906.6
4,863.23
5,827.23
6,816.96
8,886.6
11,437.22
15,565.9
19,520.65
25,814.27
34,009.85
51,618.18
54,427.2
Basic EPS, GAAP
1,482
1,687
1,472
1,386
1,528
1,766
3,447
4,716.62
4,067
7,571
8,941
15,893
16,990.13
Free Cash Flow per Basic Share
-800.89
2,038.36
656.5
179.89
-2,569.86
1,005.38
-314.61
4,193.32
4,174.18
5,117.99
9,655.3
14,185.44
14,259.95
Dividend per Share
- -
- -
200.36
301.74
297.15
315.05
311.79
508.13
633.01
744.64
980.18
1,128.89
- -
Book Value per Share
2,702.59
17,103.69
18,256.7
19,149.49
20,891.67
22,197.68
25,424.37
30,617.96
34,433.24
42,459.18
51,917.28
66,347.89
67,076.36
Tangible Book Value per Share
2,529.83
16,924
17,809.24
18,794.03
16,058.66
17,574.63
21,352.82
26,328.8
30,641.49
39,324.53
48,703.37
63,320.8
64,102.72
Basic Weighted Avg Shares
6
8
9
9
9
9
10
10
10
10
10
10
10
Sales/Revenue/Turnover
24,765
37,455
45,953
54,470
64,281
83,872
108,746
154,083
194,759
261,011
350,115
536,289
565,479
Operating Margin (%)
46.09
42.97
30.69
27.25
13.54
22.73
30.74
34.07
33.85
35.35
36
39.98
40.18
Depreciation Expense
762
1,031
1,143
1,306
5,020
7,683
8,360
9,552
10,602
11,996
13,645
15,815
16,235
Net Income, GAAP
8,838
12,878
13,909
12,956
14,408
16,667
32,774
46,689
40,577
76,551
92,043
165,121
176,522
Effective Tax Rate (%)
20.32
20.44
20.19
18.7
21.57
19.85
17.92
16.44
19.64
23.28
23.2
22.29
24.15
Profit Margin (%)
35.69
34.38
30.27
23.78
22.41
19.87
30.14
30.3
20.83
29.33
26.29
30.79
31.22
Working Capital
8,394
127,056
120,261
105,472
90,289
85,883
91,555
158,787
193,092
190,566
471,724
649,068
649,508
LT Debt
2,700
- -
- -
- -
1,830
2,160
3,097
43,345
45,185
523
2,338
860
2,085
Total Equity
24,768
156,747
172,465
182,152
218,874
228,424
264,411
328,359
371,656
462,195
569,441
723,878
732,476
Return on Invested Capital (%)
- -
13.45
6.77
6.8
3.39
6.71
10.43
12.71
12.53
14.86
17.41
24.23
24.52
Return on Capital (%)
- -
14.16
8.51
7.56
8.96
8.9
13.26
14.02
9.83
16.75
18.29
25.81
26.1
Return on Common Equity (%)
- -
14.19
8.47
7.39
7.65
8.2
14.42
16.95
12.51
19.71
18.93
26.88
27.99

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9,867
9,635
7,160
LT Borrowings
443
434
433
LT Finance Leases
529
426
1,652
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
6,244,178
4,187,028
3,106,505

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
691,644
759,542
787,960
Cash, Cash Equivalents & STI
539,205
614,372
630,775
Accounts Receivable, Net
50,481
44,490
46,379
Inventories
71,055
82,702
86,661
Total Current Liabilities
92,041
110,473
138,452
Payables & Accruals
- -
- -
- -
ST Debt
9,867
9,635
7,160
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.8%
22.41%
27.12%
Free Cash Flow
-326.75%
-264.54%
48.27%
Net Income, GAAP
34.23%
43.53%
79.39%
Sales/Revenue/Turnover
30.88%
37.89%
53.18%
Total Cash Common Dividend
- -
32.94%
16.23%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
74,717
83,107
89,209
103,083
350,115
2025
116,910
140,607
135,426
143,345
536,289
2026
146,100
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,772
3,058
2,413
1,799.17
8,941
2025
3,482
4,562.66
4,713.53
3,134.94
15,893
2026
4,579.01
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
26.95
980.18
2025
- -
- -
- -
- -
1,128.89
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ji-Hoon Sohn
Full Time Employees
526
Sector
Health technology
Industry
Pharmaceuticals: major
Address
77-19, Gwahakdanji-ro Gangneung-si GG South Korea 25452
IPO Date
Jul 24, 2015
Website
pharmaresearch.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PharmaResearch Co., Ltd. (214450.KQ) operates as a biopharmaceutical company specializing in regenerative medicine, developing and commercializing aesthetic injectables, pharmaceuticals, medical devices, cosmetics, and functional foods primarily in South Korea with expanding global operations. The company offers its flagship Rejuran skin booster based on proprietary DOT (DNA Optimizing Technology) derived from salmon DNA for skin regeneration; Re-An eye drops for ocular treatment; Rejuvenex; functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands; cosmeceuticals; dietary supplements; high-frequency stimulators; cosmetic devices; hospital and organic cosmetics; botulinum toxin products; as well as engaging in software development, consulting, venture investment, and real estate leasing. Founded in 1993 and headquartered in Seongnam-si, South Korea, with key facilities in Gangneung, Wonju, and Seongnam, the company serves domestic and international markets including exports to numerous countries and targets aesthetic clinics, healthcare providers, and consumers seeking regenerative and beauty solutions. In September 2024, PharmaResearch secured KRW 200 billion investment from global private equity firm CVC via redeemable convertible preferred shares to fund overseas mergers and acquisitions, local subsidiary establishments, R&D upgrades, and product pipeline expansion; in August 2025, it established a European distribution partnership with Laboratoires VIVACY for Rejuran across 22 countries including the UK, Germany, and France; and in November 2025, partnered with Kris Jenner for REJURAN Cosmetics anti-aging innovation.